IHO1 (Cancer/testis antigen 74) in the Breast, Lung, and Gastrointestinal Tract

Target Name: IHO1

NCBI ID: G339834

IHO1

IHO1 (Cancer/testis antigen 74) in the Breast, Lung, and Gastrointestinal Tract

IHO1 (Cancer/testis antigen 74) is a protein that is expressed in a variety of tissues, including the breast, lung, and gastrointestinal tract. It is also expressed in the testes and has been identified as a potential drug target for cancer. IHO1 is a glycoprotein with a molecular weight of approximately 18 kDa. It is composed of two chains, A and B, that are held together by a disulfide bond.

IHO1 is involved in several cellular processes, including cell adhesion, migration, and invasion. It is a cell surface protein that is involved in the development and maintenance of cancer stem cells. IHO1 has also been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Drug Targeting

IHO1 is a potential drug target because of its involvement in several cellular processes that are associated with the development and progression of cancer. One of the main targets for IHO1 is the inhibition of its signaling pathways. IHO1 has been shown to play a role in the development of cancer stem cells, and it is possible that inhibiting its signaling pathways could be a effective way to treat cancer.

Anti-IHO1 Therapies

There are several anti-IHO1 therapies that are currently being developed or tested in clinical trials. These therapies include:

1. Monoclonal antibodies: Monoclonal antibodies, also known as antibodies-based therapies, are laboratory-made versions of specific antibodies that can be used to target specific proteins. IHO1 has been the focus of several monoclonal antibodies, including AEB-197 and AEB-886. These antibodies are designed to bind to specific amino acid residues on IHO1 and can be used to inhibit its signaling pathways.
2. Small molecules: Small molecules, such as inhibitors of protein kinases, are often used to inhibit the signaling pathways of IHO1. These small molecules can be used in combination with antibodies to enhance the effectiveness of the anti-IHO1 therapies.
3. Adjuvants: Adjuvants, such as Taxol, are often used in combination with antibodies to enhance the effectiveness of the anti-IHO1 therapies. Taxol is a chemotherapy drug that is commonly used to treat breast cancer and can be used in combination with antibodies to enhance the effectiveness of the therapies.

Conclusion

IHO1 is a protein that is involved in several cellular processes that are associated with the development and progression of cancer. It is a potential drug target because of its involvement in the development of cancer stem cells and its role in the development of neurodegenerative diseases. Currently, several anti-IHO1 therapies are being developed or tested in clinical trials, including monoclonal antibodies, small molecules, and adjuvants. Further research is needed to determine the effectiveness of these therapies and to develop more effective treatments for cancer.

Protein Name: Interactor Of HORMAD1 1

Functions: Required for DNA double-strand breaks (DSBs) formation in unsynapsed regions during meiotic recombination. Probably acts by forming a complex with MEI4 and REC114, which activates DSBs formation in unsynapsed regions, an essential step to ensure completion of synapsis. Not required for HORMAD1 functions in pairing-independent synaptonemal complex formation, ATR recruitment to unsynapsed axes, meiotic silencing of unsynapsed chromatin (MSUC) or meiotic surveillance

The "IHO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IHO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets